Bristol-Myers Lung-Cancer Drug Disappoints in Trial Analysis

Updated on
  • Drugmaker says trial design may have influenced negative data
  • Bristol-Myers results contrast with Merck’s in similar group

Bristol-Myers Squibb Co.’s immune-based therapy Opdivo fell short of already low expectations in study results that throw into question whether the drug can help lung-cancer patients who’ve just been diagnosed.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.